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35 years. On 1 September 2005 the government’s
response to the committee’s report showed serious
reflection on these issues.10 The government has
accepted many of the committee’s recommendations,
but too often its response has not gone far enough.
The committee recommended that the Department
of Trade and Industry should take responsibility for rep-
resenting the interests of the pharmaceutical industry,
enabling the Department of Health to concentrate
solely on the regulation of medicines and the protection
and promotion of health. The government rejected this
recommendation on the grounds that “the interests of
patients and the industry are not exclusive” and that the
industry’s role in producing innovative medicines
beneficial to health should be considered together with
its economic investment in the United Kingdom. In this
political context there is a considerable risk that public
health will not be given sufficient priority whenever the
commercial interests of pharmaceutical companies
diverge from, or conflict with, health needs.
Since 1996 fewer than half of the drug innovations
(new molecular entities) in the United States have
offered real therapeutic advances.9 Many are “me too”
drugs: minor molecular modifications of existing
products. They satisfy the technical definition of innova-
tion and seek a slice of a lucrative market, but contribute
little or no therapeutic advance for patients. The House
of Commons Health Select Committee recommended
that the UK Medicines and Healthcare Products
Regulatory Agency (MHRA) should be more proactive
in stimulating the industry to develop drugs of real
therapeutic value and “therapeutic gain.” Despite recog-
nising that the existence of a large number of “me too”
drugs creates difficulties for prescribers, the government
remains unwilling to direct the development of drugs
towards more meaningful new treatments.
The committee also felt that the deluge of promo-
tional material doctors receive from pharmaceutical
companies is excessive and insufficiently counterbal-
anced by independent information, especially when
the manufacturer seeks to establish a market position
for a newly launched drug and patients are most at risk
because little is known about the product. The govern-
ment, on the other hand, believes that the industry’s
current self regulation of drug promotion is accept-
able. Nevertheless, the MHRAmay extend its vetting of
promotional materials to all new molecular entities
and may impose additional restrictions when new
drugs are first released on to the market.
The government now seems to embrace the idea of
patients reporting their own adverse drug reactions
using the Yellow Card scheme that is already used by
prescribers. However, the government ignored the
committee’s call for the Department of Health and the
MHRA to investigate the extent, cost, and implications
of drug induced illness in our communities and to pave
the way for rational cost-benefit assessment of
medicines.
Issues of secrecy, transparency, and public account-
ability in the drug regulatory system pervaded almost
every aspect of the inquiry. The government agrees that
the regulatory system should be as transparent as possi-
ble. It has promised to provide public access to informa-
tion on licensing applications for individual drugs, to the
data supporting authorisation for marketing, and to
assessments of medicines on which regulatory action is
taken. This is a considerable and welcome shift in think-
ing and policy, but these commitments must also be
implemented in practice.
The committee recommended that the MHRA
should make public the material it receives from drug
companies along with its assessments as soon as they are
complete. This would enable scientists and doctors to
scrutinise and engage with the agency’s decision making
processes and would ensure that drug regulation was
publicly defensible and hence more robust. The govern-
ment, however, insists on reaching regulatory decisions
about applications for new drug licences before allowing
any public access to such information. At least, though,
the government has agreed that the MHRA should be
independently reviewed every four or five years.
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SSRIs and gastrointestinal bleeding
Gastroprotection may be justified in some patients
There are theoretical reasons for believing thatselective serotonin reuptake inhibitors (SSRIs),widely used to treat depression, might increase
the risk of gastrointestinal bleeding. Gastroprotective
drugs are advocated for high risk patients taking non-
steroidal anti-inflammatory drugs, another class of
drug that causes gastrointestinal bleeding. What is the
evidence that this advice should be extended to
patients receiving SSRIs?
Serotonin is released from platelets in response
to vascular injury and promotes vasoconstriction and
a change in the shape of the platelets that leads to
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aggregation.1 Platelets cannot themselves synthesise
serotonin. SSRIs inhibit the serotonin transporter,
which is responsible for the uptake of serotonin into
platelets. It could thus be predicted that SSRIs would
deplete platelet serotonin, leading to a reduced ability
to form clots and a subsequent increase in the risk of
bleeding.
We have reviewed the published database studies
on the relation between SSRI use and gastrointestinal
bleeding. Four of these studies compared the risk of an
upper gastrointestinal bleed in those prescribed SSRIs
with those who were not. The odds ratios of a bleed in
an SSRI-treated patient ranged from 1.38 to 3.6: 3.0
(95% confidence interval 2.1 to 4.4),2 3.6 (2.7 to 4.7),3
2.1 (0.6 to 8.3),4 and 1.38 (0.82 to 2.34).5 This roughly
threefold increase in risk may also hold for other types
of bleeding. Movig et al reported that patients taking
SSRIs were 3.71 (1.35 to 10.18) times more likely to
require a blood transfusion during orthopaedic
surgery than patients not taking them.6 Meijer el al
reported that women taking SSRIs with a high affinity
for the serotonin transporter were 3.0 (0.8 to 4.9) times
more likely to experience abnormal uterine bleeding
than women who took antidepressants with low affinity
for this transporter.4
An association between the risk of bleeding and
increasing affinity for the serotonin transporter has been
noted in several studies,2 4 7 although the confidence
intervals around the quoted odds ratios overlap consid-
erably. Clomipramine, fluoxetine, sertraline, and parox-
etine have a high affinity for the serotonin transporter
while citalopram, fluvoxamine, and venlafaxine have
intermediate affinity. Low affinity drugs include doxepin,
mirtazepine, moclobemide, and nortriptyline.
Risk decreases to the same level as controls in past
users of SSRIs, indicating that bleeding is likely to be
associated with the drug rather than the illness it was
prescribed for.3 The association also holds when age,
gender, and the effects of other drugs such as aspirin
and non-steroidal anti-inflammatory drugs are con-
trolled for.
The mechanisms by which non-steroidal anti-
inflammatory drugs and SSRIs are associated with
gastrointestinal bleeding are different. Non-steroidal
anti-inflammatory drugs directly damage the gastro-
intestinal mucosa, while SSRIs reduce the effectiveness
of the normal clotting mechanism. Aspirin does both.
The absolute additional risk of an upper gastrointesti-
nal bleed (requiring admission to hospital) with an
SSRI prescribed alone is about 1 in 300 patient years,
but co-prescription of SSRIs with aspirin increases the
risk to 1 in 200 and with non-steroidal anti-
inflammatory drugs to 1 in 80.3 The risk with a
non-steroidal drug alone is 1 in 200.8
The well established association between non-
steroidal anti-inflammatory drugs and upper gastroin-
testinal bleeding is estimated to result in 700-2000
deaths/year in the UK.8 9 This has led to the
recommendation that patients in high risk groups
should receive gastroprotection in the form of an H2
antagonist, proton pump inhibitor, or misoprostil.10
High risk groups are defined as patients older than 65
years, those with a history of peptic ulcer or
gastrointestinal bleed, those who are debilitated, and
those receiving other drugs that are associated with an
increased risk of bleeding such as warfarin and
corticosteroids. Yet only misoprostol has been proved
to reduce the risk of serious bleeds. Proton pump
inhibitors have been shown to reduce endoscopically
diagnosed mucosal damage and heal ulcers induced by
non-steroidal anti-inflammatory drugs but not to
reduce the incidence of severe gastrointestinal bleeds.10
SSRIs are widely prescribed in the general popula-
tion and for elderly people. Almost 14 million
prescriptions were dispensed in community pharma-
cies in England in 2003.11 They are recommended by
the National Institute for Health and Clinical
Excellence as first line treatments in patients with at
least moderate depression.12
Gastroprotection is unlikely to be justified in
patients who receive SSRIs alone, but those who are
also taking non-steroidal anti-inflammatory drugs or
aspirin are clearly at increased risk. This increased risk
may also apply to those who are very old or have a his-
tory of gastrointestinal bleeding. The use of antide-
pressants with low affinity for the serotonin transporter
should be considered in these patients. Gastroprotec-
tive agents have not been shown to reduce the risk of
bleeds associated with SSRIs alone or in combination
with non-steroidal drugs, but until such studies are
conducted we recommend that SSRIs are added to the
list of drugs that increase the risk of bleeding induced
by non-steroidal anti-inflammatory drugs and suggest
that gastroprotection should be considered in patients
who are prescribed both SSRIs and non-steroidal anti-
inflammatory drugs or aspirin, including those under
the age of 65.
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